Navigation Links
Halozyme to Host Third Quarter Financial Results Conference Call
Date:11/1/2012

SAN DIEGO, Nov. 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2012 on Thursday, November 8, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 402796.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson  
Executive Director  
Halozyme Therapeutics  
858-704-8264  
aerickson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Reports Second Quarter 2012 Financial Results
2. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
3. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
4. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
5. Halozyme Reports First Quarter 2012 Financial Results
6. Halozyme to Host First Quarter 2012 Financial Results Conference Call
7. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
8. PDL BioPharma to Announce Third Quarter 2012 Financial Results on November 5, 2012
9. Cumberland Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. HeartWare Schedules Third Quarter Conference Call And Webcast
11. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology:
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... is affiliated with NCPDP, announced today that it has awarded a $40,000 grant ... in NCPDP’s SCRIPT Standard for ePrescribing. CancelRx enables prescribers to electronically cancel a ...
(Date:9/25/2017)... ... September 25, 2017 , ... PITTSBURGH...An inventor, from Richmond Hill, ... charts in hospitals and medical facilities, so he invented the COMPLETE PATIENT CHART. , ... charts. In doing so, it offers an improved alternative to paper charts and clipboards. ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... of the nationally syndicated The Sharon Kleyne Hour Power of Water, Global Climate ... us to shift our Olympic focus from a once-every-four-years series of events to ...
(Date:9/25/2017)... ... September 25, 2017 , ... Lean Management techniques applied ... of First-Defect-Stop for laboratory weighing is designed to help laboratory personnel ... have negative consequences on downstream processes. , If a problem is detected, the ...
(Date:9/25/2017)... , ... September 25, 2017 , ... Bobbie Horowitz was ... Osteoarthritis and multiple health issues. As a cabaret and theater producer, Horowitz would manage ... main source of transportation in New York City, so she had to take a ...
Breaking Medicine News(10 mins):